Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
RMD logo RMD
Upturn stock ratingUpturn stock rating
RMD logo

ResMed Inc (RMD)

Upturn stock ratingUpturn stock rating
$275.38
Last Close (24-hour delay)
Profit since last BUY14.91%
upturn advisory
Consider higher Upturn Star rating
BUY since 81 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: RMD (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

19 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $291.86

1 Year Target Price $291.86

Analysts Price Target For last 52 week
$291.86 Target price
52w Low $199.07
Current$275.38
52w High $293.81

Analysis of Past Performance

Type Stock
Historic Profit -23%
Avg. Invested days 35
Today’s Advisory Consider higher Upturn Star rating
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Large-Cap Stock
Market Capitalization 40.32B USD
Price to earnings Ratio 28.99
1Y Target Price 291.86
Price to earnings Ratio 28.99
1Y Target Price 291.86
Volume (30-day avg) 19
Beta 0.77
52 Weeks Range 199.07 - 293.81
Updated Date 08/29/2025
52 Weeks Range 199.07 - 293.81
Updated Date 08/29/2025
Dividends yield (FY) 0.75%
Basic EPS (TTM) 9.5

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-07-31
When -
Estimate 2.48
Actual 2.55

Profitability

Profit Margin 27.22%
Operating Margin (TTM) 33.87%

Management Effectiveness

Return on Assets (TTM) 14.02%
Return on Equity (TTM) 25.86%

Valuation

Trailing PE 28.99
Forward PE 26.39
Enterprise Value 39962081363
Price to Sales(TTM) 7.83
Enterprise Value 39962081363
Price to Sales(TTM) 7.83
Enterprise Value to Revenue 7.95
Enterprise Value to EBITDA 21.28
Shares Outstanding 146415008
Shares Floating 145480712
Shares Outstanding 146415008
Shares Floating 145480712
Percent Insiders 0.8
Percent Institutions 64.76

ai summary icon Upturn AI SWOT

ResMed Inc

stock logo

Company Overview

overview logo History and Background

ResMed Inc. was founded in 1989 by Peter Farrell, who spun it out of Baxter Healthcare. It focuses on developing, manufacturing, distributing, and marketing medical devices and cloud-based software solutions that diagnose, treat, and manage respiratory disorders, including sleep apnea, COPD, and other chronic diseases.

business area logo Core Business Areas

  • Sleep and Respiratory Care: ResMed designs, manufactures, and distributes a comprehensive range of CPAP (continuous positive airway pressure) and APAP (automatic positive airway pressure) devices, masks, and related accessories for the treatment of sleep apnea. They also offer diagnostic equipment, ventilation devices, and cloud-based patient monitoring systems. Key revenue generator.
  • Software as a Service (SaaS): ResMed provides cloud-based software solutions for managing patient data, improving adherence to therapy, and enhancing clinical outcomes. This includes platforms like Brightree and Propeller Health, offering solutions for home medical equipment (HME) providers and pharmaceutical companies managing respiratory diseases. Recurring revenue stream.

leadership logo Leadership and Structure

ResMed is led by CEO Mick Farrell. The company operates with a global structure, with headquarters in San Diego, California, and regional offices worldwide. The organizational structure emphasizes innovation, product development, and customer support.

Top Products and Market Share

overview logo Key Offerings

  • AirSense 10/11 Series: ResMed's AirSense 10 and 11 series are their flagship CPAP devices, known for their user-friendly design and advanced features. These devices treat sleep apnea, provide real time patient feedback, and monitor usage. Competitors include Philips Respironics (now recalling devices).
  • AirFit/AirTouch Mask Series: ResMed's AirFit and AirTouch mask series offer a variety of mask options designed for comfort and effective therapy. The AirFit F20 and AirTouch F20 are popular full-face masks, while the AirFit N20 and P10 are nasal and nasal pillow masks, respectively. Competitors include Fisher & Paykel Healthcare.
  • Brightree: Brightree is a cloud-based software platform for HME providers, offering billing, inventory management, and patient engagement solutions. This allows providers to work more efficiently and stay updated on patient progression with real-time metrics. Competitors include various HME billing software providers.
  • Astral Series: ResMed's Astral Series is a portable ventilator that provides invasive and non-invasive respiratory support for patients with chronic respiratory conditions. Competitors include Hamilton Medical and Dru00e4ger.

Market Dynamics

industry overview logo Industry Overview

The sleep apnea and respiratory care market is driven by the increasing prevalence of sleep apnea, COPD, and other respiratory disorders, as well as an aging population and rising awareness of treatment options. The market is competitive and regulated by various government health administrations.

Positioning

ResMed is a global leader in the sleep apnea and respiratory care market, known for its innovative products, strong brand reputation, and extensive distribution network. Their competitive advantages include a focus on technological innovation, cloud-based solutions, and patient-centric design.

Total Addressable Market (TAM)

The global sleep apnea devices market is projected to reach around $12 billion to $15 billion. The wider respiratory devices market is much larger. ResMed Inc. is a significant player within these markets and is positioned to take advantage of increased awareness and adoption of treatment. SaaS solutions also increase TAM potential.

Upturn SWOT Analysis

Strengths

  • Strong brand recognition
  • Extensive product portfolio
  • Global distribution network
  • Innovation in cloud-based solutions
  • Experienced management team

Weaknesses

  • Dependence on reimbursement policies
  • Exposure to regulatory risks
  • Supply chain vulnerabilities
  • Recall of Philips Respironics provides opportunity but also highlights potential issues.

Opportunities

  • Expanding into emerging markets
  • Developing new therapies and diagnostic tools
  • Acquiring complementary businesses
  • Leveraging cloud-based solutions for remote patient monitoring

Threats

  • Increased competition
  • Technological obsolescence
  • Changes in reimbursement policies
  • Economic downturns

Competitors and Market Share

competitor logo Key Competitors

  • Fisher & Paykel Healthcare (FPH.NZ)
  • Philips (PHG)
  • Invacare (IVC)

Competitive Landscape

ResMed holds a leading position due to superior technologies, quality products, established distribution network and services. Philips Respironics, although experiencing recalls, remains a formidable competitor. Fisher & Paykel Healthcare focuses on product comfort and also has a strong presence.

Major Acquisitions

Propeller Health

  • Year: 2019
  • Acquisition Price (USD millions): 225
  • Strategic Rationale: To expand ResMed's digital health offerings and provide connected solutions for respiratory care.

Medistar

  • Year: 2018
  • Acquisition Price (USD millions):
  • Strategic Rationale: Medistar is a U.S.-based healthcare software company focusing on cloud-based platforms to manage senior living. This acquisition broadens ResMed's capabilities in remote patient monitoring and digital health services for aging populations, enhancing chronic disease management.

Growth Trajectory and Initiatives

Historical Growth: ResMed has demonstrated consistent growth over the past decade, driven by increasing demand for sleep apnea treatment and expansion into new markets. Their SaaS solutions have contributed to recurring revenue growth.

Future Projections: Analysts project continued growth for ResMed, driven by increasing demand for sleep apnea treatment, the aging population, and the expansion of their SaaS business. Innovation in digital health solutions is also expected to drive future growth.

Recent Initiatives: Recent initiatives include strategic acquisitions, partnerships to expand product offerings, and investments in digital health and remote patient monitoring technologies.

Summary

ResMed is a leading player in sleep apnea and respiratory care, holding a strong market position due to its innovative products and extensive distribution network. They have consistently improved the companyu2019s financials due to solid products and a shift to subscription based services. However, the company must watch out for increased competition and regulatory changes. Diversification into SaaS is a successful strategy for future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • ResMed Investor Relations
  • Analyst Reports
  • Industry Publications

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market data is subject to change. Consult a qualified financial advisor before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About ResMed Inc

Exchange NYSE
Headquaters San Diego, CA, United States
IPO Launch date 1995-06-02
CEO & Chairman Mr. Michael J. Farrell BE, MBA, SM
Sector Healthcare
Industry Medical Instruments & Supplies
Full time employees 10600
Full time employees 10600

ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications to diagnose, treat, and manage respiratory disorders in the United States and internationally. The company operates in two segments, Sleep and Breathing Health, and Residential Care Software. It offers sleep recorders for the diagnosis and titration of sleep apnea in sleep clinics, hospitals, and at home, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry; and EasyCare Tx, a sleep lab solution. The company also provides AirView, a cloud-based system that enables remote monitoring and changing of patients' device settings; myAir, a personalized therapy management application for patients with sleep apnea that provides support, education, and troubleshooting tools for increased patient engagement and improved compliance; and connectivity module which provides a cellular connection between compatible ventilation devices and AirView system. In addition, the company offers Brightree solutions which are solutions and services for organizations in home medical equipment and pharmacy, orthotic and prosthetic, and home infusion; HEALTHCAREfirst solutions that offers electronic health record, software, billing and coding services, and advanced analytics that enables home health and hospice agencies to optimize clinical, financial and administrative processes; MatrixCare EHR software as a service solutions used by skilled nursing and senior living providers, life plan communities, and home health and hospice sectors; and MEDIFOX DAN software solutions that is used by residential care providers, such as home health and nursing home providers. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.